GlassScriptPhysician profile
Charles R Nathan
NPI 1477723799
$19,481.85
in general payments reported to CMS, 2019-2025
14 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $485 · 2021: $582 · 2022: $630 · 2023: $1,674 · 2024: $626 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $2,507 · Travel and Lodging: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,809.00 |
| Food and Beverage | $2,506.94 |
| Travel and Lodging | $2,376.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $13,702.95 | 2023-2025 | |
| Allergan, INC. | $1,985.91 | 2019-2022 | |
| Abbvie INC. | $1,760.03 | 2023-2025 | |
| Kci USA, INC. | $922.95 | 2019 | |
| Sientra, INC. | $194.72 | 2020-2022 | |
| Tepha INC | $164.63 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $162.11 | 2019 | |
| Revance Therapeutics, INC. | $135.72 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $121.89 | 2019-2021 | |
| Becton, Dickinson and Company | $114.65 | 2022 | |
| Mentor Worldwide LLC | $109.01 | 2019-2022 | |
| Motiva USA, LLC | $60.62 | 2025 | |
| Solventum Corporation | $33.13 | 2025 | V.A.C. Veraflo, Prevena |
| Cumberland Pharmaceuticals, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.